<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04786275</url>
  </required_header>
  <id_info>
    <org_study_id>190416008</org_study_id>
    <nct_id>NCT04786275</nct_id>
  </id_info>
  <brief_title>Evaluation of the Nociception Guided by NoL Index and PK of Fentanyl in Pediatric Patients Under General Anesthesia</brief_title>
  <acronym>NoLPedFenta</acronym>
  <official_title>Evaluation of the Nociception Guided by NoL Index and Pharmacokinetics of Fentanyl in Pediatric Patients Under General Anesthesia for Non-cardiac Elective Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pontificia Universidad Catolica de Chile</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fentanyl is one of the most common used opioids for analgesia during general anesthesia,&#xD;
      however there are few studies that describe the relationship between its pharmacokinetics and&#xD;
      pharmacodynamics, especially in the pediatric population. The monitoring of the analgesia&#xD;
      component during general anesthesia has been traditionally by changes in patient's vital&#xD;
      signs, with new devices that measure nociceptive indexes like the Nociception level (NoL)&#xD;
      index currently being validated for adults. There is still lacking evidence with nociceptive&#xD;
      indexes in the pediatric population.&#xD;
&#xD;
      Insufficient dose of opioids may cause sympathetic response, respiratory complications,&#xD;
      development of persistent post-surgical pain and even prolonged hospitalization. In the other&#xD;
      hand, and overdose of opioids may cause over sedation, postoperatory nausea and vomiting,&#xD;
      respiratory depression, hyperalgesia and tolerance.&#xD;
&#xD;
      Given the lack of evidence on the Pharmacokinetic and pharmacodynamic (PK/PD) of fentanyl in&#xD;
      this group of patients, has led to raise the development of this observational prospective&#xD;
      study; which is to describe a PK/PD model of fentanyl in pediatric population, through&#xD;
      evaluation of the NoL index, in patients submitted to elective general non-cardiac surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be invited to participate before surgery, the inclusion criteria will be&#xD;
      revised and the informed consent will be signed by one of the parents or legal tutor.&#xD;
&#xD;
      In the operating room will be recorded demographic data and relevant background such as: Age,&#xD;
      Weight, Size, BMI.&#xD;
&#xD;
      Afterwards, in the operating room, the patient will be monitored regularly: EKG, pulse&#xD;
      oximetry, non invasive blood pressure.&#xD;
&#xD;
      Induction of anesthesia with sevoflurane 6% in 100% oxygen, once loss of consciousness, 2&#xD;
      peripheral IV lines will be installed, one for medication and the other in the contralateral&#xD;
      arm for blood samples. After that, a laryngeal mask device (LMA) appropriate for the weight&#xD;
      for the management of the airway. In addition, the EEG will be monitored through a frontal&#xD;
      electroencephalographic monitoring (BIS) system and a NoL index sensor, both of which will be&#xD;
      recorded throughout the surgery.&#xD;
&#xD;
      Once all monitors are installed, a caudal block with 0,5-1 ml of bupivacaine 0,25% will be&#xD;
      performed, in the left decubitus lateral position. Ventilator and vaporizer adjustments for&#xD;
      an EtCO2 of 35-40 mmHg and a BIS index of 50-60 with Sevoflurane. After 12 minutes, because&#xD;
      of the latency of caudal block; surgeons may start. If an effective caudal block is proven,&#xD;
      the study will continue; if there is movement of the child, laryngospasm or an increase of&#xD;
      more than 10% in the base values of heart rate or blood pressure, the patient will be&#xD;
      excluded from the study.&#xD;
&#xD;
      Standardized nociceptive stimulus will be administered through a tetanic stimulus (70 Hz, 80&#xD;
      mA) for 5 seconds in the forearm. An initial tetanic stimulus will be performed, 2 minutes&#xD;
      afterwards a unique dose of fentanyl of 2 micrograms per kg will be administered. New tetanic&#xD;
      stimulus will be applied at 5, 15, 30 and 45 minutes after the fentanyl dose and blood&#xD;
      samples for fentanyl plasmatic levels will be taken at the same time in the operating room&#xD;
      and at 75 or 120 minutes in the post anesthesia care unit (PACU). NoL index values will be&#xD;
      recorded after each tetanic stimulus.&#xD;
&#xD;
      After surgery, sevoflurane will be discontinued, LMA removed and the patients transferred to&#xD;
      the PACU. Pain scores will be evaluated in the PACU using Visual analogue scale. Analgesic&#xD;
      management with NSAIDs and Acetaminophen.&#xD;
&#xD;
      PK/PD profile of fentanyl will be evaluated with NONMEM (non-linear mixed effects modelling)&#xD;
      software for the analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>NoL index.</measure>
    <time_frame>Since induction of anesthesia until emergence of anesthesia (one hour in average)</time_frame>
    <description>Variations in the NoL index (0-100). NoL has a range from 0-100, with 0 indicates no pain and 100 indicates worst pain. Data will also be analyzed using nonlinear mixed effect modeling (NONMEM)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of the plasmatic levels of fentanyl</measure>
    <time_frame>5, 15, 30, 45, 75 until 120 minutes after one dose of fentanyl.</time_frame>
    <description>Describe the change of the levels of fentanyl plasmatic levels (ng/mL) measured by high pressure liquid chromatography (HPLC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>5, 15, 30, 45, 75 until 120 minutes after one dose of fentanyl.</time_frame>
    <description>Calculate maximum plasma concentration (Cmax) fentanyl plasma levels measured with high pressure fluid (HPLC) after a single bolus of fentanyl in enrolled pediatric patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemodynamics</measure>
    <time_frame>At time of surgery, up to 120 minutes.</time_frame>
    <description>Arterial pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate (bpm)</measure>
    <time_frame>At time of surgery, up to 120 minutes</time_frame>
    <description>Heart rate (bpm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse oximetry</measure>
    <time_frame>At time of surgery, up to 120 minutes.</time_frame>
    <description>% oximetry saturation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bispectral index</measure>
    <time_frame>At time of surgery, up to 120 minutes</time_frame>
    <description>Depth of anesthesia will be recorded with BIS monitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain in Visual analogue scale (0-10)</measure>
    <time_frame>Every 15 minutes in the PACU, up to 120 minutes</time_frame>
    <description>Postoperative pain will be evaluated with Visual analogue scale (0-10), being a score of 10 worst outcome, in the PACU for 120 minutes immediately after surgery.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pain</condition>
  <condition>Anesthesia</condition>
  <condition>Pediatric ALL</condition>
  <arm_group>
    <arm_group_label>Tetanic stimulation</arm_group_label>
    <description>Single arm study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>Standard dose of 2 ug/kg after tetanic stimulation.</description>
    <arm_group_label>Tetanic stimulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tetanic stimulation</intervention_name>
    <description>Standard tetanic stimulation will be used as the stimulus to evaluate response of the intraoperative pain index (NoL) at a standard fentanyl dose.</description>
    <arm_group_label>Tetanic stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        ASA I or II children from 3 up to 10 years requiring elective non-cardiac surgery, under&#xD;
        general anesthesia and caudal block.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children 3-10 years old&#xD;
&#xD;
          -  ASA I - II&#xD;
&#xD;
          -  Lower abdominal or urological surgery, requiring general anesthesia and caudal block&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Obese patients&#xD;
&#xD;
          -  ASA III - IV - V&#xD;
&#xD;
          -  Allergy to fentanyl&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
          -  Patients with sleep apnea&#xD;
&#xD;
          -  Surgeries anticipated to have an increased volume exchange or transfusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan C Pedemonte, MSc, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pontificia Universidad Catolica de Chile</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francisco Cruzat, MD</last_name>
    <phone>976498951</phone>
    <email>fjcruzat@uc.cl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Victor Contreras, MSN, RN</last_name>
    <phone>223549217</phone>
    <email>vecontre@uc.cl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pontificia Universidad Catolica de Chile</name>
      <address>
        <city>Santiago</city>
        <state>Region Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Contreras, MSN</last_name>
      <phone>223549217</phone>
      <email>vecontre@uc.cl</email>
    </contact>
    <investigator>
      <last_name>Francisco Cruzat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alejandro Gonzalez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mauricio Ibacache, PhD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ignacio Cortinez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Victor Contreras, MSN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela Muñoz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <reference>
    <citation>Ziesenitz VC, Vaughns JD, Koch G, Mikus G, van den Anker JN. Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review. Clin Pharmacokinet. 2018 Feb;57(2):125-149. doi: 10.1007/s40262-017-0569-6. Review. Erratum in: Clin Pharmacokinet. 2017 Nov 24;:.</citation>
    <PMID>28688027</PMID>
  </reference>
  <reference>
    <citation>Lötsch J. Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage. 2005 May;29(5 Suppl):S90-103. Review.</citation>
    <PMID>15907650</PMID>
  </reference>
  <reference>
    <citation>Renaud-Roy E, Stöckle PA, Maximos S, Brulotte V, Sideris L, Dubé P, Drolet P, Tanoubi I, Issa R, Verdonck O, Fortier LP, Richebé P. Correlation between incremental remifentanil doses and the Nociception Level (NOL) index response after intraoperative noxious stimuli. Can J Anaesth. 2019 Sep;66(9):1049-1061. doi: 10.1007/s12630-019-01372-1. Epub 2019 Apr 17.</citation>
    <PMID>30997633</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 27, 2021</study_first_submitted>
  <study_first_submitted_qc>March 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pontificia Universidad Catolica de Chile</investigator_affiliation>
    <investigator_full_name>Francisco Cruzat</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>NoL</keyword>
  <keyword>Nociception level</keyword>
  <keyword>Fentanyl</keyword>
  <keyword>Pediatric anesthesia</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Analysis plan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

